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The efficacy of nicardipine, a new calcium ion antago-
nist, was studied in 39 patients aged 42 to 70 years with
chronic stable angina in two different placebo-controlled
single- and double-blind crossover trials and with long-
term follow-up, using serial quantitated exercise testing
and ambulatory ST segmentmonitoring. In the first study
the minimal effective dose was determined, and in the
repeat study the effectsof three different dose levelswere
evaluated. Treadmill exercise testing was performed at
the end of each 2 week treatment period with on-line
computer analysis of the electrocardiogram. The mean
(± standard error of the mean) exercise time was 6.8
± 0.7 minutes on placebo and 7.0 ± 0.8 minutes during
treatment with nicardipine, 60 mg/day (p = NS). This
increased to 8.7 ± 0.8 (p < 0.001)and 9.2 ± 0.9 minutes
(p < 0.001) with 90 and 120 mg/day, respectively. The
Movement of calcium ions across myocardial and vascular
smooth muscle cells plays a vital role in their contractile
function and in the maintenance of tone. The drugs that
block the movement of extracellular calcium into the cells
are known as calcium antagonists, calcium flux inhibitors,
slow channel blocking agents and calcium channel blocking
agents, a situation that reflects disagreement about their
precise mode of action. Despite this disagreement (I), these
drugs have been hailed as a significant advance in the treat-
ment of cardiovascular diseases (2). They have been shown
to be effective in the control of stable and unstable angina
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mean heart rate at rest during placebo administration
was 75 ± 2 beats/min and increased to 85 ± 3, 84 ±
2 and 88 ± 3 beats/min (p < 0.02, p < 0.01, p < 0.01,
respectively) at each dose level. The time taken to de-
velop 1 mm of ST segment depression was prolonged
from 4.8 ± 0.6 minutes during placebo administration
to 5.3 ± 0.7 (p = NS), 6.4 ± 0.7 (p < 0.01) and 6.7
± 0.8 minutes (p < 0.001), respectively, at each dose
level.
The improvement achieved after 2 weeks of nicar-
dipine, 120 mg daily, was maintained over a period of 6
months of follow-up. Three patients were withdrawn,
one taking 60 mg of nicardipine, one taking 90 mg of
nicardipine and one taking placebo, but the overall in-
cidenceof side effectswas low. Nicardipine is an effective
antianginalagent withan optimaldoseof90to 120mg/day.
(3-10), hypertension (I 1,12), arrhythmias (I3) and cardio-
myopathies (I4). A large number of these drugs are currently
undergoing clinical trials, but to date only three, verapamil,
nifedipine and diltiazem, are available for clinical use in
the United Kingdom and United States.
Nicardipine is a new calcium ion antagonist that has been
shown to be effective in hypertension (I5) and is undergoing
intense investigation as an antianginal agent. The drug is
structurally and pharmacologically closely related to nifed-
ipine (Fig. 1), exhibiting both calcium antagonist and phos-
phodiesterase inhibitory properties (16). The initial impres-
sion was that it would be similar in potency to nifedipine
in equivalent doses, so we tested this suggestion by means
of a placebo-controlled dose titration study. This informa-
tion was then used to design a second study to compare the
efficacy of three dose levels of nicardipine as measured by
objective variables derived from multistage graded exercise
testing and 24 hour ambulatory ST segment monitoring in
patients with chronic stable angina due to obstructive coro-
nary artery disease.
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Figure 1. Molecular structure of nifedipine and
nicardipine.
Single-Blind Comparison of Placebo
and Nicardipine
Methods
Patients. Twenty male patients aged 45 to 69 years with
chronic stable angina were entered into the first clinical trial,
after all previous antianginal medications had been with-
drawn for at least 2 weeks. All patients had chest pain
relieved by rest and sublingual nitroglycerin and at least
I mm horizontal or downsloping ST segment depression on
standardized treadmill exercise testing. Patients with a re-
cent myocardial infarction (within 4 months), unstable an-
gina, clinical congestive heart failure, blood pressure at rest
of 160/100 mm Hg or more or insulin-dependent diabetes
mellitus were excluded, as were pre-menopausal women.
No patient received digitalis, diuretic drugs or other car-
diovascular agents before or during the study; the only med-
ications administered were the study drugs and sublingual
nitroglycerin for anginal attacks. These inclusion criteria
have been reported previously (5,6,17).
Trial design. This trial was single-blind placebo-
controlled. A 2 week placebo run-in phase was followed by
two 2 week periods of nicardipine therapy, 10 mg and 20
mg three times daily. Multistage graded exercise tests were
performed at the completion of each treatment period as
described previously (17-19); hematologic and biochemical
analysis was performed at the same time. Student's paired
t test (two-tailed) was used for the statistical analysis. In-
formed consent was obtained from each patient, and the
trial was approved by the Hospital Ethical Committee.
Results (Table 1)
All 20 patients completed the study. The mean ± stand-
ard error of the mean exercise time of 6.4 ± 0.5 minutes
during placebo administration increased to 7.4 ± 0.7 min-
utes with 30 mg of nicardipine daily (p < 0.01) and to 7.8
± 0.7 minutes with 60 mg of nicardipine daily (p < 0.00 I).
The time to I mm ST depression in lead CCs of 4.8 ± 0.5
minutes during placebo administration increased to 5.5 ±
0.7 minutes with 30 mg of nicardipine daily (p < 0.05) and
to 6.1 ± 0.7 minutes with 60 mg of nicardipine daily (p
< 0.00 I). The heart rate at rest of 71 ± 3 beats/min during
placebo administration increased to 79 ± 4 beats/min with
60 mg of nicardipine daily (p < 0.01). One patient became
angina-free on treadmill testing while taking 60 mg of ni-
cardipine daily.
Table 1. Exercise Test Data on Nicardipine in 20 Patients With Chronic Stable Angina*
p Values
Nicardipine Nicardipine
Placebo vs. Nicardipine
Placebo (30 mg/day) (60 mg/day) 30 mg/day 60 mg/day
1. Exercise time (min) 6.4 ± 0.5 7.4 ± 0.7 7.8 ± 0.7 <0.01 <0.001
2. Heart rate at rest (beats/min) 71 ± 3 75 ± 4 79 ± 4 NS <0.01
3. Maximal heart rate (beats/min) 123 ± 3 127 ± 4 129 ± 3 NS NS
4. M-ST (CMs) (mm) 1.8 ± 0.2 1.8 ± 0.2 1.6 ± 0.1 NS NS
5. M-ST (CCs) (mm) 1.8 ± 0.1 1.7 ± 0.2 1.7 ± 0.\ NS NS
6. 1 mm time in CMs (min) 4.8 ± 0.5 5.4 ± 0.7 5.6 ± 0.7 NS NS
7. 1 mm time in CCs (min) 4.8 ± 0.5 5.5 ± 0.7 6.\ ± 0.7 <0.05 <0.001
8. Heart rate gain 53 ± 3 52 ± 3 49 ± 3 NS NS
9. Rate-pressure product (peak units) 162 ± 8 162 ± 9 166 ± 7 NS NS
*Data are expressed as mean ± standard error of the mean. M-ST = maximal ST segment depression; NS = not significant; 1 mm time = time
taken to develop 1 mm ST depression relative to rest level; p = probability.
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Double-Blind Comparison of Nicardipine and
Placebo and Long-Term Follow-Up
Methods
Patients. Nineteen patients (I8 men and 1 woman) aged
42 to 70 years with grade II or III exertional chronic stable
angina pectoris (the Canadian Cardiovascular Society cri-
teria)(20) entered the second trial. The same inclusion and
exclusion criteria were used as in the first trial.
Trial design. A basal exercise test was performed after
withdrawing all antianginal drugs with the exception of gly-
ceryl trinitrate silver for pain was stopped for 2 weeks. Each
patient then entered a double-blind crossover phase of pla-
cebo and nicardipine, 60 mg daily, followed by two single-
blind phases of nicardipine, 90 mg and 120 mg daily. Each
leg of the crossover consisted of 2 weeks with the drug
being administered in three doses daily. After these periods,
the trial was continued on an open basis for 6 months. Eleven
men entered this long-term follow-up study and each re-
ceived nicardipine, 120 mg daily, in three divided doses.
Exercise testing. The effect of the placebo and nicar-
dipine was assessed both subjectively and objectively. The
patients maintained a detailed diary of the frequency of their
anginal attacks and the number of sublingual glyceryl trin-
itrate tablets consumed. They were clearly instructed about
the importance of keeping an accurate diary and of not taking
sublingual nitrates prophylactically.
Objective evaluation was achieved by performing serial
maximal treadmill exercise tests before entry into the trial
and after administration of all medication, active or inactive,
at 2 week intervals. In the long-term follow-up study, ex-
ercise tests were performed after 6, 18 and 26 weeks of
continuous nicardipine therapy. All exercise tests were per-
formed in the morning at least 2 hours after a light breakfast
and at 120 to 180 minutes after the administration of the
last dose of tablets. The patients arrived at the exercise
laboratory at least 30 minutes before the test and rested
comfortably. They were instructed not to smoke or take
glyceryl trinitrate tablets on the morning of the test.
Exercise protocol. The exercise test was performed with
a microcomputer-based system (Marquette: computer as-
sisted system for exercise) linked to a Quinton treadmill. A
modified Balke treadmill protocol was used for each test
(Table 2) . The speed and gradient were automatically con-
trolled by the computer and the test was timed with a built-
in digital clock to an accuracy of 0.1 minute (5 ,6,17-19) .
All tests were continued until the patients developed symp-
toms. The criteria for cessation were angina (grade Il) , pain
in the legs, severe breathlessness or fatigue. Standard safety
procedures and legal requirements as recommended for adult
exercise testing laboratories by the American Heart Asso-
ciation (21) were observed. Two bipolar electrocardio-
graphic leads were continuously monitored at rest, during
Table 2. Treadmill Exercise Protocol
Stage Time (min) Speed (miles/h) Gradient (% incline)
I 3 2 0
2 3 3 4
3 3 3 8
4 3 3 12
5 3 3 16
6 3 3 20
7 3 4.5 20
exercise and for a minimum of 5 minutes after exercise.
Systolic blood pressure was monitored at rest and every 3
minutes during exercise using a mercury sphygmomanometer.
The monitored leads were CM5 (manubrium stemi neg-
ative and LV5 exploring electrode) and CC5 (RV6 negative
and LV5 exploring electrode), and a lead showing large P
waves was used to monitor arrhythmias . The electrocardio-
gram at rest was passed to the computer to form the rest
template. The computer calculated ST segment depression
at the J point in reference to the most horizontal part of the
PR segment and expressed the result in multiples of 0.1
mm. The averaged ST segment depression, heart rate and
ectopic beat count were printed automatically for both leads
every minute during and after exercise. The electrocardio-
gram during the entire test was recorded continuously as 25
beat averages at a paper speed of I mrn/s with ectopic
complexes being recorded in real time . At the end of the
test, the computer printed out the exercise time, maximal
ST depression and ectopic complex count. A continuous
trend graph of heart rate and ST depression in all three leads
was also obtained (Fig . 2) . The measurement circuits of the
computer were calibrated every day .
Exercise data analysis. From the continuous printouts
the following data were available: I) exercise time; 2) heart
rate and ST segment levels at rest; 3) maximal heart rate;
4) maximal ST depression (in leads CMs and CC5) ; and 5)
exercise heart rate, ST levels and ectopic complex count
every minute during and after exercise .
Thefollowing variables could then be calculated: 1) heart
rate gain == maximal heart rate - heart rate at rest; 2) heart
rate recovery in 5 minutes == maximal heart rate - heart
rate 5 minutes after recovery; 3) I mm time == time taken
for developing I mm ST segment depression relative to the
rest level; 4) maximal ST depression == ST segment depres-
sion immediately at the point of termination of exercise,
corrected for rest values; 5) maximal ST depression/exercise
time; 6) ST recovery in 5 minutes postexercise; and 7) rate-
pressure product == systolic blood pressure at peak of ex-
ercise x maximal heart rate and ~ 100.
Ambulatory electrocardiographic monitoring. Twenty-
four hour ambulatory Holter monitoring was performed us-
ing a frequency-modulated tape recorder (Oxford Medilog
Mark 2) and methods we have previously described (22-24).
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MaxilUi Lateral ST Dep (IIII)/ST Bar (I11III) of -3.1/-3.1 occurred 7.2 Min. into exercise
evaluation.
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Figure 2. Continuous trend plot of ST
segment depression (first panel) and ST
bar (second panel) during exercise test-
ing. Time is on the horizontal axis with
each marker representing 2 minutes, and
ST depression is on the vertical axis with
each marker showing I mm. The end of
exercise is shown by a vertical line in the
middle of each panel. Heartrate, ectopic
beat count and blood pressure plot are
shown in the third panel. Dep =
depression; PAC = premature atrialcom-
plex; PVC = premature ventricular
complex.
Tape analysis was performed in three stages:
1. Visual inspection. The tape signal was recalled using
an Oxford PB4 replay unit and displayed on a Reynolds
Medical Pathfinder (Reynolds Medical). The quality of the
tape recording and any gross abnormalities were appraised
by the operator during this phase.
2. Analog printout. The tape was then removed and if
suitable for analysis, played back into the Pathfinder using
the trend system to identify the ST segment. The trend
system generated two bright spots" one of which was placed
manually on the PR isoelectric line and the other at the J
point. The electrocardiogram was then displayed continu-
ously and the system measured the voltage difference be-
tween these two points averaged for 10 beats with automatic
rejection of artifact and ectopic complex counts. The system
performed simultaneous RR interval analysis, and the ST
segment and heart rate changes were registered graphically
as an analog trend chart using two channels of a linear
recorder; the analyzer related the changes to the standard
calibration signals. This presentation permitted rapid visual
assessment of patterns of ST depression or elevation that
could be related to time events from the patient's diary card
and was amenable to semiquantitative analysis.
3. Quantitative analysis. The digital system was de-
signed to work with the Reynolds Medical ST trend system.
An interfacing module was built to enable the calibrated
heart rate and ST segment change from the trend system to
be transferred into a minicomputer (MINe PDP 11/23) with
twin 8 inch (20.3 cm) floppy disk drives. The computer was
programmed to give an on-line data analysis option and an
off-line data retrieval and analysis option.
The initial program "menu" consisted of the patient
identification, recorder identification, the electrocardio-
graphic leads recorded, starting time of the recording, times
of symptoms and the date of the recording. The zero ref-
erence point was transferred to the computer together with
the I mY square wave calibration pulses recorded on each
tape. The computer was programmed to reject noisy or
distorted calibration signals and produce an average of 15
pulses. If a satisfactory calibration signal was not obtained,
a standard internal calibration could be utilized. The tape
deck was then started and the signals passed continuously
into the computer. The computer program also contained
noise rejection and artifact-sensing circuitry. Once the tape
was run through, the data were transferred to a floppy disk
for future analysis and retrieval. The entire procedure of
digitizing took about I hour per tape for two channels of
electrocardiogram. The data stored on each disk were mean,
maximal and minimal heart rate and mean, maximal and
minimal ST depression for every minute. Software pro-
gramming enabled the operator to recall any period either
as minute values or as averaged values. The operator could
preset variable normal limits, and the total time duration
and the mean ST change were also available to allow cal-
culation of the area of ST depression in a given time. In
addition, the off-limit ST values or heart rate values could
be edited out or included and identified by distinct markers.
With this program, digital analysis could be performed in
less than 1 minute per sequence after the data had been
stored. A graphic plotting program enabled a trend to be
generated from digital values within 30 seconds.
During each visit, the patients were questioned in detail
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Table 3. Exercise Test Values on Placebo and Nicardipine in 16 Patients With Chronic Stable Angina
Nicardipine p Values
Placebo 60 mg daily 90 mg daily 120 mg daily PI P2 P3 P4
1, Exercise time (min) 6,8 ± 0,7 7.0 ± 0,8 8,7 ± 0.8 9.2 ± 0.9 NS <0.001 <0.001 NS
2. Heart rate at rest (beats/min) 75 ± 2 85 ± 3 84 ± 2 88 ± 3 <0,02 <0.01 <0,01 NS
3. Maximal heart rate (beats/min) 121 ± 3 127 ± 3 133 ± 4 134 ± 4 <0.01 <0.001 <0.001 NS
4, Heart rate gain 46 ± 3 43 ± 3 49 ± 3 48 ± 3 NS NS NS NS
5. Heart rate recovery in 5 min 48 ± 2 47 ± I 47 ± 3 46 ± 3 NS NS NS NS
6. M-ST in CM s (mm) 1.7 ± 0.2 1.6 ± 0,2 1.6 ± 0.2 1.9 ± 0.2 NS NS NS NS
7. M-ST in CCs (mm) 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.6 ± 0.2 NS NS NS NS
8. I mm time in CM s (min) 4.8 ± 0,6 5,3 ± 0,7 6.4 ± 0.7 6.7 ± 0.8 NS <0.01 <0,001 NS
9, I mm time in CCs (min) 4.8 ± 0.6 5.5 ± 0,7 7,2 ± 0.8 7.2 ± 0.8 <0.05 <0.001 <0.001 NS
10. M-ST/Ex time in CM s 0.31 ± 0,05 0,31 ± 0.06 0.23 ± 0.04 0.27 ± 0,05 NS <0.01 NS NS
(mm/min)
II. M-ST/Ex time in CCs 0.27 ± 0,04 0,27 ± 0.04 0.20 ± 0.03 0.21 ± 0,04 NS <0.01 NS NS
(mm/min)
12. ST recovery in 5' in CM s (mm) 1.5 ± 0.2 1.3 ± 0.2 1.4 ± 0,2 1.3 ± 0.2 NS NS NS NS
13. ST recovery in 5' in CCs (mm) 1.2 ± 0,1 r.i ± 0.2 1.3 ± 0.2 1.2 ± 0,2 NS NS NS NS
14. Rate-pressure product 178 ± 7 180 ± 8 205 ± 8 197 ± 10 NS <0.01 NS NS
(peak units)
15. Systolic blood pressure at rest 133 ± 4 i27 ± 3 127 ± 3 125 ± 4 NS NS NS NS
(mm Hg)
16. Systolic blood pressure at peak 147 ± 4 141 ± 5 154 ± 4 147 ± 5 NS NS NS NS
exercise (mm Hg)
Values are expressed as mean ± standard error of the mean, Ex time = exercise time; M-ST = maximal ST segment depression; NS = not
significant; p = probability; PI = P values between nicardipine 60 mg daily vs, placebo; P2 = p values between nicardipine 90 mg daily vs, placebo;
P3 = P values between nicardipine 120 mg daily vs. placebo; P4 = p values between nicardipine 120 mg vs. nicardipine 90 mg daily.
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Informed consent was obtained from each patient and the
protocol was approved by the Hospital Ethical Committee.
Figure 4. Effect of nicardipine (N) in three daily doses and pla-
cebo (P) on ST segment variables. M-ST ~ = maximal ST depres-
sion; other abbreviations as in Figure 3.
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from a standard questionnaire and examined for pedal edema,
raisedjuguiar venous pressure and basal crepitations. Blood
was drawn for routine biochemical and hematologic inves-
tigations at each visit. Statistical analysis was performed
using Student's paired t test and analysis of variance (25).
Figure 3. Effect of placebo (P) and nicardipine (N) in a dose of
60, 90 and 120 mg daily on exercise time (Ex. time) and I mm
ST depression time (I mm time CMs). All values arc mean ±
standard error of the mean. NS = not significant; p = probability.
*
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Figure 5. Effect of placebo (P) and nicardipine (N) in three daily
doses on heart rate (HR) variables. Max = maximal.
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Figure 6. Mean hourly heart rates for 24 hours in 16 patients
treated with placebo and nicardipine 40 mg three times daily. The
probability value refers to the comparison between placebo and
active drug.
the study: one patient who developed ventricular tachycardia
on the third week of the double-blind crossover phase while
taking placebo, one patient who developed unstable angina
while taking nicardipine, 60 mg daily, and one patient taking
nicardipine, 90 mg daily, who developed severe headache
and nausea.
Exercise tolerance (Table 3, Fig. 3). All the patients
developed angina during treadmill exercise at the end of the
placebo phase. The mean ± standard error of the mean
exercise time to angina during placebo administration was
6.8 ± 0.7 minutes. This increased to 7.0 ± 0.8 minutes
with nicardipine, 60 mg daily (p = NS), 8.7 ± 0.8 minutes
with nicardipine, 90 mg daily (p < 0.001) and 9.2 ± 0.9
minutes with nicardipine, 120 mg daily (p < 0.001). There
was no significant difference in exercise tolerance at doses
of 90 and 120 mg of nicardipine. Two patients taking 90
mg and three taking 120 mg daily of nicardipine became
free of angina during treadmill testing. No patient became
angina-free taking nicardipine, 60 mg daily.
ST segment changes (Table 3, Fig. 3 and 4). The mean
± standard error of the mean exercise time required to
develop 1 mm ST segment depression from the rest level
in lead eMs was 4.8 ± 0.6 minutes with placebo and it
increased to 5.3 ± 0.7 (p = NS), 6.4 ± 0.7 (p < 0.01)
and 6.7 ± 0.8 minutes (p < 0.001) with 60, 90 and 120
mg, respectively, of nicardipine. The peak ST segmentchange
on termination of exercise increased from - 1.7 ± 0.2 mm
with placebo to -1.9 ± 0.2 mm with nicardipine, 120 mg
(p = NS). There were no significant differences in ST
recovery after placebo and nicardipine therapy.
Heart rate (Table 3, Fig. 5). The mean heart rate at
rest of 75 ± 2 beats/min during placebo administration
Table 4. Ambulatory ST Segment Variables (leads CMs and CCs) in 16 Patients Treated With Placebo and Nicardipine, 60, 90 and
120 mg Daily*
p Values
Nicardipine
PL vs. Nicardipine
Placebo 60 mg 90 mg 120 mg 60 mg 90 mg 120 mg
CMs
I. Episodes of ST dep > I mm in 24 hours 43 ± 18 66 ± 27 32 ± 14 22 ± 14 NS NS NS
2. Mean ST dep in 24 hours (mm) 1.1 ± 02 0.9 ± 0.2 0.9 ± 0.2 0.8 ± 0.2 NS NS NS
3. Max depth of ST dep in 24 hours (mm) 1.7 ± 0.4 1.7 ± 0.4 1.6 ± 0.3 1.2 ± 0.3 NS NS NS
CCs
I. Episodes of ST dep > I mm in 24 hours. II ± 4 20 ± 7 20 ± 8 15 ± 8 NS NS NS
2. Mean ST dep in 24 hours (mm) 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 0.8 ± 0.2 NS NS NS
3. Max depth of ST dep in 24 hours (mm) 1.4 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 l.l ± 0.3 NS NS NS
*All values are mean ± standard error of the mean. dep = depression; max = maximal; NS = not significant.
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increased to 85 ± 3 (p < 0.02) , 84 ± 2 (p < 0.0 1) and
88 ± 3 beats/min (p < 0.0 1) with 60, 90 and 120 mg,
respectively, of nicardipine. Similarly. heart rate at peak of
exerci se increased from 12 1 ± 3 beats/min during placebo
administration to 127 ::!: 3 beats/min (p < 0 .0 1) with 60
rng , 133 ± 4 (p < 0.00 1) with 90 mg and 134 ± 4 (p <
0.001) with 120 mg of nicardipine , respectively. The ab-
solute heart rate gain during each treatment phase was not
statistically different from that attained during placebo
administration . There was no change in the heart rate re-
covery time in the postexercise period, and the peak rate-
pressure product was not altered by treatment. Rest and
peak systolic blood pressures were not altered by nicardipine
therapy.
Angina frequency. The mean number of anginal attacks
per week with placebo administration was six. This did not
change with 60 mg of nicardipine, but decreased to three
attacks with 90 and 120 mg of nicardipine daily. Similarly,
the mean glyceryl trinitrate consumption of five tablets per
week with placebo increased to eight tablets with 60 mg.
and decreased to four tablets with 90 and 120 mg of nicar-
dipine daily.
Twenty-four hour ambulatory monitoring (Table 4,
Fig . 6). No patient showed prolongatio n of the PR interval
or higher degrees of heart block. The mean number of min-
utes in which the ST segment was depressed more than I
mm in lead eMs was 43 ± 18 during placebo administration
and there was no significant change with nicardipine ther-
apy . The maximal depth of ST segment depression was 1.7
± 0.4 mm with placebo and this also was not significantly
altered by nicardipine therapy . The hourly mean heart rate
was increased during treatme nt with nicardipine, 120 mg
daily , between 10 and I I AM and was reduced between I
and 2 PM.
Long-ter m effects (Table 5, Fig. 7 and 8). Eleven pa-
tients participated in the long-term follow-up study. taking
nicardipine, 120 mg daily, in 3 divided doses . All patients
were followed up for 18 weeks, and 5 for 26 weeks . Mul-
tistage graded exercise tests were performed after 6, 18 and
26 weeks of conti nuous administration of nicardipine.
The mean ± standard error of the mean exerc ise time
of 7.7 ± 0 .7 minute s with placebo administration increased
to 11.9 ± 0.6 minutes after 6 weeks, I 1.2 ± 0.8 minutes
after 18 weeks and 13.3 ± 0.7 minutes after 26 weeks of
nicardipine therapy (p < 0.001 versus placebo at all stages).
Similar improvement in other variables was maintained over
the follow-up period. Seven of the II patients at week 6,
4 of the II patients at week 18 and 2 of the 5 patients at
week 26 became free of angina on treadmill exercise testing.
Adverse reactions. Three patients were withdrawn from
therapy. One developed severe angina and ventricular tachy-
cardia during the third week of the crossover phase ; this
patient was taking placebo at that time . One patient was
withdrawn because of severe headache and nausea after I
week of taking nicardi pine 30 mg three times daily . The
third patient was withdrawn during the third week of the
Table 5. Long-Term Effects of Nicardipine , 120 mg Daily, in II Patients
p Values
Nicardipine (120 mg daily) PL vs. Nicardipine
Placcbo 6 Weeks 18 Weeks 26 Weeks 6 Weeks 18 Weeks 26 Weeks
1. Exercise lime (min) 7.7 ± 0 .7 11.9 ± 0.6 11.2 ± 0.8 13.3 ± 0.7 < 0.00 1 < 0.001 <0.001
2. Heart rate at rest (beats/min) 76 ± 3 88 ± 2 86 ± 3 84 ± 4 < 0.01 < 0.02 NS
3. Maximal heart rate (beats/min) 125 ± 4 138 ± 5 142 ± 5 151 ± 7 < 0.001 < 0.00 1 < 0.0 1
4. Heart rate gain 48 ± 3 50 ± 4 56 ± 5 66 ± 5 NS NS < 0.0 1
5. Heart rate recovery in 5 min 49 ± 2 44 ± 3 50 ± 3 57 ± 3 NS NS < 0.02
6. I mm time in CMs (min) 5.3 ± 0.7 8.2 ± 0.8 7.3 ± 0.8 7.6 ± 1.4 < 0.02 < 0.02 < 0.05
7. I mm time in CCs (min) 5.2 ± 0.7 9.4 :!: 0.9 7.9 ± 0.8 7.5 ± 1.3 < 0.001 < 0.01 < 0.02
8. M-ST in CMs (mm) 1.8 ± 0.2 2.0:!: 0.3 2.0 ± 0.4 3.2 ± 0.8 NS NS NS
9. M-ST in CCs (mm) 1.5 ± 0.2 1.7 ± 0.3 1.8 ± 0.3 3.1 ± 0.8 NS NS NS
10. ST recovery in CMs (mm) 1.5 ± 0.2 1.4 :!: 0.2 1.6 .!:: 0.4 2.6 ± 0.5 NS NS < 0.02
II. ST recovery in CC, (mm) 1.2 ± 0.1 1.3 ± 0.2 1.5 ± 0.3 2.3 ± 0.4 NS NS < 0.05
12. M-ST/Ex time in CM, 0.3 ± 0.04 0.2 ± 0.03 0.2 ± 0.03 0.2 ± 0.05 NS < 0.05 NS
(mm/min)
13. M-ST/Ex time in CCs 0 .2 ± 0 .03 0.2 ± 0.03 0.2 ± 0.02 0.2 ± 0.04 NS NS NS
(mm/min)
14. Rate-pressure product 175 ± 6 206 :!: 10 222 ± 10 222 :!: 9 < 0.0 1 < 0.001 < 0.0 1
(peak units)
15. Rest systolic blood pressure 130 ± 4 118 ± 4 128 ± 3 118 ± 2 < 0.05 NS < 0.05
(mmHg)
16. Peak systolic blood pressure 148 ± 4 149 ± 5 155 ± 3 148 ± 2 NS NS NS
(mm Hg)
Values are expressed as mean ± standard error of the mean. Ex = exercise; M-ST = maximal ST segment depression; NS = nol significant;
p = probability; PL = placebo.
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Weeks of treatment
Figure 7. Effectof long-termnicardipine therapyon exercisetime
to development of angina and I mm ST segment depression in
lead eMs . The numbers on the graphs at each period indicate the
numberof patients studied. All values are mean ± standarderror
of the mean. P = placebo; p = probability.
crossover phase due to unstable angina while taking nicard-
ipine, 20 mg three times daily. Three patients reported pedal
edema, and 3 patients reported flushing of the face while
taking 40 mg of nicardipine three times daily. One patient
complained of dyspnea and three reported headaches on the
highest dose. One patient also reported tachycardia and
tiredness on the highest dose . No serum biochemical ab-
normalities were recorded during this study .
During the long-term study, one patient reported pedal
edema and dyspnea after 16 weeks of continuous therapy.
Generally, nicardipine in a dose of 30 and 40 mg three times
daily was well tolerated with few side effects.
Discussion
Advances in angina treatment: the development of
slow calcium channel blocking drugs. There have been
important advances in therapy aimed at preventing anginal
attacks for the last 20 years. Beta-adrenoreceptor blocking
drugs have become widely used and produce symptomatic
and objective improvement in more than 50% of patients
with chronic stable angina (26-29) . Calcium channel block-
ing agents have been widely used for vasospastic angina
Weeks of treatment
Figure 8. Effect of long-term nicardipine therapy on heart rate
(HR) variables duringexercisetesting. Abbreviations and symbols
as in previous figures . Max = maximal.
(30-34) and have also been found useful in chronic stable
angina (5-8,24,35). Verapamil, diltiazem and nifedipine
are in clinical use for these indications in most countries.
Having established that the first generation of calcium block-
ing agents are effective therapeutic agents, intensive re-
search is under way to produce new drugs with improved
efficacy, longer duration of action and fewer side effects.
Particular problems have arisen with verapamil, which causes
constipation , and nifedipine, which causes headaches, flush-
ing and palpitation in susceptible patients (17). Molecular
manipulation and slow release formulations are some of the
methods that have been used to reduce these side effects .
For example, gallopamil is a verapamil analog that has the
addition of a methoxy radical. It is equally effective to ver-
apamil and seems to have fewer side effects, especially
constipation (5) , which occurs in 30% of patients with ver-
apamil (17) . Nifedipine in a slow release formula produces
lower serum levels and is likely to have a reduced incidence
of headache, flushing and palpitation (12) .
Similarity of nicardipine and nifedipine. Nicardipine
is structurally and pharmacologically closely related to ni-
fedipine (Fig. 1). Both drugs are dihydropyridine derivatives
and are equally effective slow calcium channel blocking
agents (15,16). However, nicardipine appears to produce
fewer side effects in doses up to 120 mg daily. The initial
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impression was that nicardipine would be similar in potency
to nifedipine in equivalent doses.
Nicardipine: efficacy and mode of action. We have
studied four dose levels of nicardipine and found it to be
equally effective in doses of 30 and 40 mg three times daily.
Exercise tests were spaced at a minimum of 2 weeks interval
during the short-term study to eliminate the training effect
that was also removed in the long-term study where the tests
were performed at longer intervals. Maximal improvement
in exercise tolerance was achieved after 6 weeks of contin-
uous nicardipine therapy in a dose of 40 mg three times
daily. Like nifedipine, nicardipine increased the heart rate
at rest at each dose level and the maximal increase of 13
beats/min was recorded on the highest dose (p < 0.01).
Similarly, the maximal heart rate was increased at each dose
level, but there was no significant change in the heart rate
gain during nicardipine therapy as compared with placebo
therapy. Studies suggest that it is also effective in hyper-
tension (15), rest angina and coronary vasospasm (36). Our
findings suggest that nicardipine is equal in potency to ni-
fedipine in approximately twice the daily dose, with rela-
tively fewer side effects than we have previously docu-
mented in a double-blind controlled study comparing
verapamil with nifedipine (17). In order to acquire com-
parative data, the protocol was identical to that used in all
our previous clinical trials. These methods of evaluation
were designed to yield objective data with a minimal of
observer bias, and an opportunity to examine the mode of
action of the drugs being studied (18).
Of particular note is the finding of no change in the rate-
pressure product during nicardipine treatment despite a sig-
nificant improvement in exercise tolerance. This indicates
that nicardipine has quite a different mode of action from
beta-adrenoreceptor blocking drugs and we suggest that not
only may it have a direct action effecting a reduction in
coronary arterial tone but it may also act by improving
myocardial oxygen consumption at the cellular level. This
drug is still under investigation and may prove to be useful
when used in combination with a beta-adrenoreceptor block-
ing agent to reduce its effect on heart rate.
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